Scholars Central

Mini reviewPublished 12 Nov 2021

Reduced fluence corneal cross-linking in mild to moderate keratoconus: A review.

Authors: Fateme Alipour, Parya Abdolalizadeh

Journal of Clinical Ophthalmology

Volume 5 · Pages 489–491

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Keratoconus progression, especially at younger ages, is aggressive and may not stop on its own. The idea of improving biomechanical strength of the cornea to prevent disease progression and decrease its optical consequences and possibly need to corneal transplantation was a dream which almost came true. Since then, CXL has been approved by Food and Drug Administration and become a robust treatment option for progressive keratoconus as well as other conditions including post-LASIK ectasia. The chemical interaction of UVA and riboflavin is the basic principle of CXL which increases interfibrillar covalent bonds through photo polymerization of riboflavin and activation of oxidative pathways

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Clinical Ophthalmology.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical Ophthalmology
  • SubjectOphthalmology & Optometry
  • BylineArticles whose byline prints “Fateme Alipour”
  • BylineArticles whose byline prints “Parya Abdolalizadeh”